Discovery Value Fund’s Intellia Therapeutics NTLA Stock Holding History

Discovery Value Fund’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-97,976	Closed	-$881K	–	2
2025 Q4	$881K	Sell	97,976 -130,725	-57%	-$1.8M	2.35%	2
2025 Q3	$3.95M	Hold	228,701	–	–	7.05%	3
2025 Q2	$2.15M	Sell	228,701 -332,860	-59%	-$2.73M	4.16%	3
2025 Q1	$3.99M	Hold	561,561	–	–	5.66%	3
2024 Q4	$6.55M	Hold	561,561	–	–	3.76%	4
2024 Q3	$11.5M	Hold	561,561	–	–	5.93%	3
2024 Q2	$12.6M	Hold	561,561	–	–	6.39%	3
2024 Q1	$15.4M	Hold	561,561	–	–	5.35%	4
2023 Q4	$17.1M	Hold	561,561	–	–	7.82%	2
2023 Q3	$17.8M	Hold	561,561	–	–	9.73%	3
2023 Q2	$22.9M	Hold	561,561	–	–	11.62%	3
2023 Q1	$20.9M	Sell	561,561 -11,389	-2%	-$447K	10.54%	3
2022 Q4	$20M	Sell	572,950 -11,533	-2%	-$548K	5.79%	5
2022 Q3	$32.7M	Hold	584,483	–	–	8.21%	4
2022 Q2	$30.3M	Sell	584,483 -401,690	-41%	-$20.4M	6.33%	5
2022 Q1	$71.7M	Sell	986,173 -4,579	-0.5%	-$388K	5.28%	7
2021 Q4	$117M	Buy	990,752 +68,341	+7%	+$8.56M	4.31%	6
2021 Q3	$124M	Sell	922,411 -7,258	-0.8%	-$1.1M	3.63%	6
2021 Q2	$151M	Buy	929,669 +783,179	+535%	+$61M	4.08%	7
2021 Q1	$11.8M	Buy	+146,490	New	+$9.83M	0.38%	13

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Discovery Value Fund's NTLA Position: Q1 2026 in Review

Discovery Value Fund sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 97,976 shares — an estimated $881K sold.

Discovery Value Fund first reported a position in NTLA in Q1 2021 and held it in 20 quarters. The position peaked at $151M in Q2 2021. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Discovery Value Fund reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Discovery Value Fund sold 97,976 Intellia Therapeutics shares in Q1 2026, an estimated $881K.
Discovery Value Fund first reported a position in Intellia Therapeutics in Q1 2021 and held it in 20 quarters.
Discovery Value Fund's Intellia Therapeutics position peaked at $151M in Q2 2021.
304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Discovery Value Fund's 13F filing for Q1 2026, filed 14 May 2026.